Chloroquine retinopathy may progress long after drug cessation

Article

Despite treatment, chloroquine retinopathy may continue to progress long after drug cessation, according to a study published on-line by the British Journal of Ophthalmology. Further, disease progression may be accompanied by cystoid macular oedema, epiretinal membrane formation and peripheral involvement.

Despite treatment, chloroquine retinopathy may continue to progress long after drug cessation, according to a study published on-line by the British Journal of Ophthalmology. Further, disease progression may be accompanied by cystoid macular oedema, epiretinal membrane formation and peripheral involvement.

In order to assess the progression of morphological alterations in chloroquine or hydroxychloroquine retinopathy after drug cessation, researchers included 11 women, who underwent clinical exam, high-resolution OCT with spectral-domain OCT, fundus autofluorescence (FAF), near-infrared autofluorescence (NIA) and ultra-wide-angle autofluorescence (UW-FAF) 2.1 to 7.1 years after drug cessation.

Two patients with very limited parafoveal retinopathy had no progression within 3 years, but visual acuity in the remaining nine patients deteriorated, and the progression of retinal degeneration could be documented. FAF, UW-FAF, and NIA changes included increase of affected area, or a regional increase or decrease of FAF or NIA intensity. SD-OCT changes included reduction of retinal thickness, increased area of photoreceptor or retinal pigment epithelial loss, development or increase of cystoid macular oedema in four women, or development of epiretinal membranes in five women. Therapy of cystoid macular oedema had limited benefit.

To access this study, visit the journal's website here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.